ARRY 403

Drug Profile

ARRY 403

Alternative Names: AMG-151; ARRY-403

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Array BioPharma
  • Class Antihyperglycaemics; Small molecules
  • Mechanism of Action Glucokinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 07 Aug 2013 ARRY 403 is no longer licensed to Amgen worldwide
  • 19 Apr 2013 Amgen terminates phase I trial in Type-2 diabetes mellitus in USA (NCT01755442)
  • 01 Nov 2012 Amgen initiates enrolment in a phase I trial for Type-2 diabetes mellitus in USA (NCT01755442)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top